GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) prospects on the street are looking brighter by the day as investors take note of the expected expansion of the medical marijuana industry. The company has already made a name for itself as a legitimate marijuana play with a number of products that are already eliciting demand from consumers.  Given the growth the company has already experienced, it is emerging as a potential acquisition target.

 Takeover Chatter                

The wave of consolidation in the healthcare sector that has seen a number of companies acquired has all but continue fuel talk that GW Pharmaceutical could be acquired soon. Fueling speculation that the company could be acquired providing an opportunity for investors to generate some value are reports that the company has hired Morgan Stanley as an advisor on the acquisition talks.

The company’s drug, Sativex, which is designed to treat cancer-related pain, is seen as one of the assets that major drug companies could look to gain access to. Having already been approved in the U.S. the U.K and Canada the drug is also undergoing a late-stage trial as a novel treatment for Multiple Sclerosis.

GW Oncology Assets                                                                                            

Epidiolex another novel treatment for childhood epilepsy is also eliciting interest from other drug makers looking to bolster their portfolio of cancer treatment. The candidate drug is currently undergoing late-stage trials for two separate indications. The drug if approved could generate up to £1.4 billion in annual revenues for the company according to analysts at Cantor Fitzgerald.

The two drugs essentially make the case of why GW Pharmaceutical fits the bill when it comes to being a potential acquisition target.  However, the company can still opt to remain as a standalone company if it does not receive the desired valuation given that it is sitting on $500 million in cash pile.

 Such a move would not come as a surprise given that GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) is poised to be one of the biggest beneficiaries of more states in the US legalizing medical marijuana.

Previous articleUnited Cannabis Corp (OTCMKTS:CNAB) Posts Record Prana Sales Ahead of Hemp Industrial Processing
Next articleSkyline Medical Inc (NASDAQ:SKLN) Targets More Sales In Europe
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg,,, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.